Literature DB >> 11342625

CD8+ tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ.

S Radoja1, M Saio, A B Frey.   

Abstract

Induction of Fas-mediated activation-induced cell death in antitumor T cells has been hypothesized to permit tumor escape from immune destruction. Several laboratories have proposed that expression of Fas ligand (L) by tumor is the basis for this form of T cell tolerance. In this study, we characterized murine tumor-infiltrating lymphocytes (TIL) for activation status, cell cycle status, level of apoptosis, cytokine secretion, and proliferative capacity. TILs express multiple activation markers (circa CD69, CD95L, CD122, and LFA-1) and contain IL-2 and IFN-gamma mRNAs, but are neither cycling nor apoptotic in situ. In addition, TIL are dramatically suppressed in proliferative response and do not secrete IL-2 and IFN-gamma. However, upon purification and activation in vitro, TIL secrete high levels of IL-2 and IFN-gamma, enter S phase, and then die by Fas-mediated apoptosis. Activation by injection of anti-TCR Ab or IL-2 into tumor-bearing mice induced TIL entrance into S phase preceding apoptosis, showing that TIL have functional TCR-mediated signal transduction in situ. Our data demonstrate that TIL, not tumor, express both Fas and FasL, are arrested in G(1), do not secrete cytokine in situ, and, upon activation in vitro and in vivo, rapidly die by activation-induced cell death.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11342625     DOI: 10.4049/jimmunol.166.10.6074

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells.

Authors:  Güllü Görgün; Tobias A W Holderried; David Zahrieh; Donna Neuberg; John G Gribben
Journal:  J Clin Invest       Date:  2005-06-16       Impact factor: 14.808

2.  Suppression of proximal T cell receptor signaling and lytic function in CD8+ tumor-infiltrating T cells.

Authors:  Ngozi Monu; Alan B Frey
Journal:  Cancer Res       Date:  2007-12-01       Impact factor: 12.701

Review 3.  Costimulatory and coinhibitory receptors in anti-tumor immunity.

Authors:  Gregory Driessens; Justin Kline; Thomas F Gajewski
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

4.  Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model.

Authors:  Katherine A Waugh; Sonia M Leach; Brandon L Moore; Tullia C Bruno; Jonathan D Buhrman; Jill E Slansky
Journal:  J Immunol       Date:  2016-07-01       Impact factor: 5.422

Review 5.  Tumor-induced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8+ lymphocytes inactivates antitumor effector phase.

Authors:  Edwin J Vazquez-Cintron; Ngozi R Monu; Alan B Frey
Journal:  J Immunol       Date:  2010-12-15       Impact factor: 5.422

6.  Endogenous T cells prevent tumor immune escape following adoptive T cell therapy.

Authors:  Scott R Walsh; Boris Simovic; Lan Chen; Donald Bastin; Andrew Nguyen; Kyle Stephenson; Talveer S Mandur; Jonathan L Bramson; Brian D Lichty; Yonghong Wan
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

7.  IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments.

Authors:  Michelle R Simpson-Abelson; Vivek S Purohit; Wing Man Pang; Vandana Iyer; Kunle Odunsi; Todd L Demmy; Sandra J Yokota; Jenni L Loyall; Raymond J Kelleher; Sathy Balu-Iyer; Richard B Bankert
Journal:  Clin Immunol       Date:  2009-04-22       Impact factor: 3.969

Review 8.  Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer.

Authors:  Chrysoula I Liakou; Sowmita Narayanan; Derek Ng Tang; Christopher J Logothetis; Padmanee Sharma
Journal:  Cancer Immun       Date:  2007-06-26

9.  The virological synapse facilitates herpes simplex virus entry into T cells.

Authors:  Martine Aubert; Miri Yoon; Derek D Sloan; Patricia G Spear; Keith R Jerome
Journal:  J Virol       Date:  2009-04-01       Impact factor: 5.103

10.  Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers.

Authors:  Africa Wallace; Veena Kapoor; Jing Sun; Paul Mrass; Wolfgang Weninger; Daniel F Heitjan; Carl June; Larry R Kaiser; Leona E Ling; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.